What will happen when the trial finishes?

The trial medication won’t be available after the end of the trial, so participants won’t receive the trial medication when the trial finishes. If the trial shows a possible benefit from the sotagliflozin it is possible that sotagliflozin may become available for people with type 1 diabetes and heart failure.

We hope to finish the trial in early 2026 but it may take up to a year before we can publish the results. We’ll send participants a letter with the results once we have them. We’ll also let participants know if they received Sotagliflozin or the placebo at that point.